JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 16, 2004; DOI: 10.1124/jpet.104.074450


0022-3565/05/3122-659-668$20.00
JPET 312:659-668, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.074450v1
312/2/659    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michaelis, M. L.
Right arrow Articles by Georg, G. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michaelis, M. L.
Right arrow Articles by Georg, G. I.

NEUROPHARMACOLOGY

{beta}-Amyloid-Induced Neurodegeneration and Protection by Structurally Diverse Microtubule-Stabilizing Agents

M. L. Michaelis, S. Ansar, Y. Chen, E. R. Reiff, K. I. Seyb, R. H. Himes, K. L. Audus, and G. I. Georg

Department of Pharmacology and Toxicology (M.L.M., S.A., Y.C., K.I.S.), Department of Medicinal Chemistry (E.R.R., G.I.G.), Department of Molecular Biosciences (R.H.H.), and Department of Pharmaceutical Chemistry (K.L.A.), University of Kansas, Lawrence, Kansas

Deposition of {beta}-amyloid peptide (A{beta}) and hyperphosphorylation of the {tau} protein are associated with neuronal dysfunction and cell death in Alzheimer's disease. Although the relationship between these two processes is not yet understood, studies have shown that both in vitro and in vivo exposure of neurons to A{beta} leads to {tau} hyperphosphorylation and neuronal dystrophy. We previously reported that the microtubule-stabilizing drug paclitaxel (Taxol) protects primary neurons against toxicity induced by the A{beta}25-35 peptide. The studies in this report were undertaken to characterize the actions of paclitaxel more fully, to assess the effectiveness of structurally diverse microtubulestabilizing agents in protecting neurons, and to determine the time course of the protective effects of the drugs. Primary neurons were exposed to A{beta} in the presence or absence of several agents shown to interact with microtubules, and neuronal survival was monitored. Paclitaxel protected neurons against A{beta}1-42 toxicity, and paclitaxel-treated cultures exposed to A{beta} showed enhanced survival over A{beta}-only cultures for several days. Neuronal apoptosis induced by A{beta} was blocked by paclitaxel. Other taxanes and three structurally diverse microtubule-stabilizing compounds also significantly increased survival of A{beta}-treated cultures. At concentrations below 100 nM, the drugs that protected the neurons did not produce detectable toxicity when added to the cultures alone. Although multiple mechanisms are likely to contribute to the neuronal cell death induced by oligomeric or fibrillar forms of A{beta}, low concentrations of drugs that preserve the integrity of the cytoskeletal network may help neurons survive the toxic cascades initiated by these peptides.


Received for publication July 24, 2004
Accepted September 16, 2004.

Address correspondence to: Dr. M. L. Michaelis, Department of Pharmacology and Toxicology, 1251 Wescoe Hall Dr., 5064 Malott Hall, University of Kansas, Lawrence KS 66045. E-mail: mlm{at}ku.edu




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
A. Pannaccione, F. Boscia, A. Scorziello, A. Adornetto, P. Castaldo, R. Sirabella, M. Taglialatela, G. F. D. Renzo, and L. Annunziato
Up-Regulation and Increased Activity of KV3.4 Channels and Their Accessory Subunit MinK-Related Peptide 2 Induced by Amyloid Peptide Are Involved in Apoptotic Neuronal Death
Mol. Pharmacol., September 1, 2007; 72(3): 665 - 673.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. A. Asuni, A. Boutajangout, D. Quartermain, and E. M. Sigurdsson
Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements
J. Neurosci., August 22, 2007; 27(34): 9115 - 9129.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
C. L. Masters and K. Beyreuther
Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A{beta} amyloid pathway
Brain, November 1, 2006; 129(11): 2823 - 2839.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. Q. Trojanowski and V. M.-Y. Lee
The Alzheimer's Brain: Finding Out What's Broken Tells Us How to Fix It
Am. J. Pathol., November 1, 2005; 167(5): 1183 - 1188.
[Full Text] [PDF]


Home page
Hum Mol GenetHome page
J. M. Gerdes and N. Katsanis
Small molecule intervention in microtubule-associated human disease
Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R291 - R300.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.